PE20010693A1 - Metodo para la determinacion de actividad alfa-secretasa sobre la app - Google Patents
Metodo para la determinacion de actividad alfa-secretasa sobre la appInfo
- Publication number
- PE20010693A1 PE20010693A1 PE2000000993A PE0009932000A PE20010693A1 PE 20010693 A1 PE20010693 A1 PE 20010693A1 PE 2000000993 A PE2000000993 A PE 2000000993A PE 0009932000 A PE0009932000 A PE 0009932000A PE 20010693 A1 PE20010693 A1 PE 20010693A1
- Authority
- PE
- Peru
- Prior art keywords
- activity
- app
- asp1
- secretase
- sequence
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 2
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 abstract 3
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 abstract 3
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 abstract 3
- 150000001413 amino acids Chemical group 0.000 abstract 3
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 3
- 239000000758 substrate Substances 0.000 abstract 3
- 238000012360 testing method Methods 0.000 abstract 3
- -1 AMINO Chemical class 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical group NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 108010054155 lysyllysine Proteins 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000002285 radioactive effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6478—Aspartic endopeptidases (3.4.23)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96472—Aspartic endopeptidases (3.4.23)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UN METODO PARA ENSAYAR LA ACTIVIDAD DE LA HU-ASP1 O-SECRETASA QUE COMPRENDE: PONER EN CONTACTO LA PROTEINA HU-ASP1 Y UN SUSTRATO DE PROTEINA PRECURSORA DE AMILOIDE (APP), QUE CONTIENE UN SITIO DE ESCICION O, ENSAYAR LA ACTIVIDAD O-SECRETASA Y DETERMINAR LA ESCICION DEL SUSTRATO APP EN EL SITIO DE ESCICION O QUE COMPRENDE LAS SECUENCIAS DE AMINOACIDOS LVFFAEDF o KLVFFAED Y ENSAYAR LA ACTIVIDAD; DETERMINAR Y COMPARAR LA ACTIVIDAD HU-ASP-1 O-SECRETASA EN PRESENCIA O AUSENCIA DE UN MODULADOR DONDE LOS MODULADORES QUE AUMENTAN LA ACTIVIDAD SON SUSTANCIAS POTENCIALMENTE TERAPEUTICAS PARA LA ENFERMEDAD DE ALZHEIMER. TAMBIEN SE REFIERE A UN POLIPEPTIDO PRODUCIDO EN UNA CELULA TRANSFORMADA O TRANSFECTADA CON UN POLINUCLEOTIDO QUE COMPRENDE UNA SECUENCIA NUCLEOTIDICA QUE CODIFICA LA PROTEASA HU-ASP1 O UNO DE SUS FRAGMENTOS QUE TIENE LA SECUENCIA 2 O CARECE DE LOS AMINOACIDOS 469-492, ADEMAS CARECE DE LOS AMINOACIDOS 493-518 O CARECE DE LOS AMINOACIDOS 1-62 AMINO TERMINALES QUE RETIENE ACTIVIDAD O-SECRETASA DE ASP, SE PURIFICA Y AISLA, EL SUSTRATO APP COMPRENDE LA ISOFORMA APP HUMANO Y ADEMAS COMPRENDE DILISINA CARBOXI-TERMINAL O UNA MARCA TERMINAL TAL COMO RADIOACTIVAS, QUIMIOLUMINISCENTES, ENZIMATICAS FLUORESCENTES
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15549399P | 1999-09-23 | 1999-09-23 | |
| US09/416,901 US6699671B1 (en) | 1998-09-24 | 1999-10-13 | Alzheimer's disease secretase, APP substrates therefor, and uses therefor |
| US16923299P | 1999-12-06 | 1999-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010693A1 true PE20010693A1 (es) | 2001-06-24 |
Family
ID=34753605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000000993A PE20010693A1 (es) | 1999-09-23 | 2000-09-22 | Metodo para la determinacion de actividad alfa-secretasa sobre la app |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1224297B1 (es) |
| AR (1) | AR025754A1 (es) |
| AT (1) | ATE431419T1 (es) |
| AU (1) | AU782312B2 (es) |
| CA (1) | CA2397786A1 (es) |
| CO (1) | CO5770112A1 (es) |
| DK (1) | DK1224297T3 (es) |
| ES (1) | ES2327312T3 (es) |
| PE (1) | PE20010693A1 (es) |
| PT (1) | PT1224297E (es) |
| TW (2) | TWI294462B (es) |
| WO (1) | WO2001023533A2 (es) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7456007B1 (en) | 1998-12-31 | 2008-11-25 | Elan Pharmaceuticals, Inc. | β-secretase enzyme compositions and methods |
| US7115410B1 (en) | 1999-02-10 | 2006-10-03 | Elan Pharmaceuticals, Inc. | β-secretase enzyme compositions and methods |
| CA2359785A1 (en) | 1999-02-10 | 2000-08-17 | John P. Anderson | .beta.-secretase enzyme compositions and methods |
| AU3770800A (en) | 1999-03-26 | 2000-10-16 | Amgen, Inc. | Beta secretase genes and polypeptides |
| JP5138851B2 (ja) | 1999-06-28 | 2013-02-06 | オクラホマ メディカル リサーチ ファウンデーション | 触媒的に活性な組換えメマプシンおよびその使用方法 |
| US7514408B1 (en) | 1999-12-02 | 2009-04-07 | Elan Pharmaceuticals, Inc. | β-secretase enzyme compositions and methods |
| CA2401749A1 (en) | 2000-03-23 | 2001-09-27 | Elan Pharmaceuticals, Inc. | Compounds and methods to treat alzheimer's disease |
| US6713276B2 (en) | 2000-06-28 | 2004-03-30 | Scios, Inc. | Modulation of Aβ levels by β-secretase BACE2 |
| CA2410680A1 (en) | 2000-06-30 | 2002-01-10 | Elan Pharmaceuticals, Inc. | Compounds to treat alzheimer's disease |
| US6846813B2 (en) | 2000-06-30 | 2005-01-25 | Pharmacia & Upjohn Company | Compounds to treat alzheimer's disease |
| PE20020276A1 (es) | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER |
| EP1666452A2 (en) | 2000-06-30 | 2006-06-07 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
| US7217556B1 (en) | 2000-12-23 | 2007-05-15 | Pfizer Inc | Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in Alzheimer's disease |
| US7601528B1 (en) | 2000-12-23 | 2009-10-13 | Elan Pharmaceuticals, Inc. | Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in alzheimer's disease |
| US7806980B2 (en) | 2000-12-23 | 2010-10-05 | Elan Pharmaceuticals, Inc. | Method for crystallizing human beta secretase in complex with an inhibitor |
| US7384773B1 (en) | 2001-05-10 | 2008-06-10 | Pfizer Inc | Crystal of HIV protease-cleaved human beta secretase and method for crystallization thereof |
| US7524668B1 (en) | 2001-05-10 | 2009-04-28 | Elan Pharmaceuticals, Inc. | Crystal of human beta secretase having monoclinic space group symmetry C2 and methods for crystallization thereof |
| CA2448834A1 (en) | 2001-06-01 | 2002-12-12 | Elan Pharmaceuticals, Inc. | Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases |
| JP2004532894A (ja) | 2001-06-13 | 2004-10-28 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病を治療するためのアミンジオール |
| MXPA04000140A (es) | 2001-06-27 | 2004-06-03 | Elan Pharm Inc | Derivados de beta-hidroxiamina utiles en el tratamiento de enfermedad de alzheimer. |
| CA2453444A1 (en) | 2001-07-10 | 2003-01-23 | Elan Pharmaceuticals, Inc. | Diaminediols for the treatment of alzheimer's disease |
| EP1404664A1 (en) | 2001-07-10 | 2004-04-07 | Elan Pharmaceuticals, Inc. | Aminediols for the treatment of alzheimer's disease |
| JP2005503144A (ja) * | 2001-07-26 | 2005-02-03 | アステック テクノロジー リミテッド | 新規ｂａｃｅタンパク質、その核酸分子、新規ｂａｃｅタンパク質の新規結晶構造、並びに製造及び使用方法 |
| US7186539B1 (en) | 2001-08-31 | 2007-03-06 | Pharmacia & Upjohn Company | Method for refolding enzymes |
| BR0213139A (pt) | 2001-10-04 | 2004-08-10 | Elan Pharm Inc | Composto, método de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto e composição farmacêutica |
| JP4547152B2 (ja) | 2001-10-23 | 2010-09-22 | オクラホマ メディカル リサーチ ファウンデーション | β−セクレターゼ阻害剤および使用方法 |
| US7045311B2 (en) | 2001-10-25 | 2006-05-16 | Monogram Biosciences, Inc. | Whole cell assay systems for cell surface proteases |
| IL161881A0 (en) | 2001-11-08 | 2005-11-20 | Upjohn Co | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives |
| DE60327250D1 (de) | 2002-02-21 | 2009-05-28 | Pharmacia & Upjohn Co Llc | Modifizierte bace |
| WO2004058686A1 (en) | 2002-04-30 | 2004-07-15 | Elan Pharmaceuticals, Inc. | Hydroxypropyl amides for the treatment of alzheimer’s disease |
| US7442537B1 (en) | 2002-05-10 | 2008-10-28 | Elan Pharmaceuticals, Inc. | Crystals of unliganded beta secretase and/or beta secretase-like proteins and the use thereof |
| JP2004000060A (ja) * | 2002-05-31 | 2004-01-08 | Otsuka Pharmaceut Co Ltd | アミロイドβ産生に影響を与える化合物のスクリーニング方法 |
| DOP2003000765A (es) | 2002-11-27 | 2004-05-31 | Elan Fharmaceuticals Inc | Ureas substituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer (substituted ureas and carbamates useful in the treatment of alzheimer`s disease |
| CA2523232A1 (en) | 2003-04-21 | 2004-11-04 | Elan Pharmaceuticals, Inc. | (hetero) arylamide 2-hydroxy-3-diaminoalkanes for use in the treatment of alzheimer's disease |
| WO2004099402A1 (en) | 2003-05-02 | 2004-11-18 | Elan Pharmaceuticals, Inc. | Glycosylation variants of bace |
| WO2005087751A2 (en) | 2004-03-09 | 2005-09-22 | Elan Pharmaceuticals, Inc. | Substituted hydroxyethylamine aspartyl protease inhibitors |
| JP2008505930A (ja) | 2004-07-09 | 2008-02-28 | エラン ファーマシューティカルズ，インコーポレイテッド | オキシム誘導体置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬 |
| US7906625B2 (en) | 2005-01-24 | 2011-03-15 | Amgen Inc. | Humanized anti-amyloid antibody |
| WO2007047305A1 (en) | 2005-10-12 | 2007-04-26 | Elan Pharmaceuticals, Inc. | Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors |
| TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
| CA2687750C (en) | 2007-07-06 | 2016-10-18 | Boehringer Ingelheim International Gmbh | Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture |
| TW201020244A (en) | 2008-11-14 | 2010-06-01 | Astrazeneca Ab | New compounds |
| EP2281824A1 (en) | 2009-08-07 | 2011-02-09 | Noscira, S.A. | Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders |
| EP2643299B1 (en) | 2010-11-22 | 2016-06-22 | Noscira, S.A. | Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09178743A (ja) * | 1995-12-27 | 1997-07-11 | Oriental Yeast Co Ltd | 可溶性ａｐｐの定量法 |
| EP0848062A3 (en) * | 1996-12-14 | 2000-07-05 | Smithkline Beecham Corporation | Aspartic protease ASP1 |
| AU1726199A (en) * | 1997-12-31 | 1999-07-19 | Chiron Corporation | Metastatic cancer regulated gene |
| KR20060111905A (ko) * | 1998-09-24 | 2006-10-30 | 파마시아 앤드 업존 캄파니 엘엘씨 | 알츠하이머병 세크레타제 |
-
2000
- 2000-09-22 PE PE2000000993A patent/PE20010693A1/es not_active Application Discontinuation
- 2000-09-22 AU AU76071/00A patent/AU782312B2/en not_active Ceased
- 2000-09-22 AT AT00965338T patent/ATE431419T1/de active
- 2000-09-22 AR ARP000104987A patent/AR025754A1/es unknown
- 2000-09-22 CA CA002397786A patent/CA2397786A1/en not_active Abandoned
- 2000-09-22 DK DK00965338T patent/DK1224297T3/da active
- 2000-09-22 CO CO00072196A patent/CO5770112A1/es not_active Application Discontinuation
- 2000-09-22 EP EP00965338A patent/EP1224297B1/en not_active Expired - Lifetime
- 2000-09-22 PT PT00965338T patent/PT1224297E/pt unknown
- 2000-09-22 ES ES00965338T patent/ES2327312T3/es not_active Expired - Lifetime
- 2000-09-22 WO PCT/US2000/026080 patent/WO2001023533A2/en not_active Ceased
- 2000-09-27 TW TW089119610A patent/TWI294462B/zh not_active IP Right Cessation
- 2000-09-27 TW TW096126353A patent/TW200745552A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2397786A1 (en) | 2001-04-05 |
| WO2001023533A3 (en) | 2002-05-10 |
| CO5770112A1 (es) | 2007-06-29 |
| EP1224297A2 (en) | 2002-07-24 |
| AU7607100A (en) | 2001-04-30 |
| TWI294462B (en) | 2008-03-11 |
| EP1224297B1 (en) | 2009-05-13 |
| DK1224297T3 (da) | 2009-09-07 |
| TW200745552A (en) | 2007-12-16 |
| AU782312B2 (en) | 2005-07-21 |
| WO2001023533A2 (en) | 2001-04-05 |
| ES2327312T3 (es) | 2009-10-28 |
| ATE431419T1 (de) | 2009-05-15 |
| PT1224297E (pt) | 2009-08-17 |
| AR025754A1 (es) | 2002-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20010693A1 (es) | Metodo para la determinacion de actividad alfa-secretasa sobre la app | |
| O'Sullivan et al. | The biology of human hair greying | |
| Egelrud et al. | hK5 and hK7, two serine proteinases abundant in human skin, are inhibited by LEKTI domain 6 | |
| ES2088426T3 (es) | Peptidos de metaloproteasas matriz: funcion en diagnostico y terapia. | |
| ATE474052T1 (de) | Verfahren zur herstellung von rekombinanten proteinen mittels inhibitoren von apoptose | |
| DE68929043D1 (de) | Für androgen-rezeptor-protein kodierende dna | |
| DE69941429D1 (de) | 1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a | |
| DE60238058D1 (de) | Verwendung von lysyloxydase inhibitoren zur zellkultur und gewebeaufbau | |
| AR006188A1 (es) | "composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion". | |
| ES2205132T3 (es) | Subunidad catalitica de la telomerasa humana. | |
| ATE437652T1 (de) | Verwendung von hmgb1 zur aktivierung dendritischer zellen | |
| TR199901569T2 (xx) | T�berk�lozun te�hisi i�in bile�ikler ve y�ntemler. | |
| DK0572478T3 (da) | HBGAD- og HIGAD-polypeptider og nukleinsyre og anvendelse heraf til diagnostik og behandling af GAD-autoantigen-associerede sygdomme | |
| ES2599781T3 (es) | Péptidos antienvejecimiento activadores del proteasoma y composiciones que los contienen | |
| WO1990003435A3 (fr) | Acide nucleique codant pour l'enzyme de conversion de l'angiotensine (eca) humaine, et ses applications, notamment pour le diagnostic in vitro de l'hypertension arterielle | |
| DK0932689T3 (da) | Assay for homocystein og homocysteindesulphurase fra protozo-trichomonas vaginalis | |
| DE3688324D1 (de) | Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel. | |
| Deshmukh et al. | Detection of proteolytic activity by covalent tethering of fluorogenic substrates in zymogram gels | |
| Tholen et al. | Contribution of cathepsin L to secretome composition and cleavage pattern of mouse embryonic fibroblasts. | |
| AR019864A1 (es) | Proceso para producir el antigeno de toxoplasma sag1 o fragmentos del mismo; proteina sag1 o fragmentos de la misma expresada en dicho proceso;composiciones de vacuna que comprendan dicha proteina sag1 o fragmentos de la misma; uso de dicha proteina para la manufactura de medicamentos para preveniry | |
| TR200201119T2 (tr) | İnsan alfa1G-C-türü kalsiyum kanalı kodlayan DNA. | |
| ATE405649T1 (de) | Hemmstoff zur diagnose und behandlung von haemophilia a patienten | |
| DK1287142T3 (da) | Nukleinsyremolekyle omfattende en for et SDF-1 gamma chemokin, en neuropeptid-præcursor eller mindst et neuropeptid kodende nukleinsyresekvens | |
| Kim et al. | The effect of bee venom acupuncture on protease activity and free radical damage in synovial fluid from collagen-induced arthritis in rats | |
| Wadosky et al. | Regulation of the calpain and ubiquitin‐proteasome systems in a canine model of muscular dystrophy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal | ||
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |